anti-CD33 CAR-T cells (University of Texas MD Anderson Cancer Center)

anti-CD33 CAR-T cells (specifically the 4-1BB/CD3z construct) are an investigational chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of myeloid malignancies, primarily acute myeloid leukemia (AML). This immunotherapy involves genetically engineering a patient's own T cells to express a CAR that specifically targets the Myeloid cell surface antigen CD33, a protein expressed on approximately 90% of AML cells. The intracellular signaling architecture of this CAR includes the 4-1BB (CD137) co-stimulatory domain and the CD3-zeta (CD3ζ) signaling chain. The incorporation of the 4-1BB domain is intended to enhance the metabolic fitness, expansion, and long-term persistence of the T cells in the patient's body, potentially leading to more durable anti-leukemic effects compared to earlier generations of CAR-T therapies. This therapy is being evaluated in early-phase clinical trials at several leading academic institutions, including MD Anderson Cancer Center, the University of Pennsylvania, Fred Hutchinson Cancer Research Center, and the Second Affiliated Hospital of Anhui Medical University.

Other names

CD33-directed 4-1BB/CD3z CAR-T cellsanti-CD33 chimeric antigen receptor T-cell therapyanti-CD-33 chimeric antigen receptor T-cell therapyanti-CD 33 chimeric antigen receptor T-cell therapyCD33-specific CAR-T cellsCD-33-specific CAR-T cellsCD 33-specific CAR-T cells